Stay updated with breaking news from Concomitant Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oral presentation delivered at the American Heart Association Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in...
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...
Median time to return to full baseline function occurred within 90 minutes following outpatient treatment with NAYZILAM® (midazolam) nasal spray, with a...
Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 -- Lexicon...
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care &